利培酮联合奥氮平治疗难治性精神分裂症的效果分析

Effect analysis of risperidone combined with olanzapine in the treatment of refractory schizophrenia

目的研究难治性精神分裂症应用利培酮联合奥氮平治疗的临床效果。方法80例难治性精神分裂症患者,按照随机数字表法分为实验组和对照组,各40例。对照组采用单纯利培酮治疗,实验组采用利培酮联合奥氮平治疗。比较两组治疗效果,不良反应发生率,治疗前后阳性及阴性症状量表(PANSS)评分。结果实验组治疗总有效率95.00%明显高于对照组的72.50%,差异有统计学意义(P<0.05)。实验组治疗前PANSS评分为(81.24±12.56)分,治疗后PANSS评分为(52.45±1.32)分;对照组治疗前PANSS评分为(81.35±12.67)分,治疗后PANSS评分为(67.87±1.45)分。治疗前,两组PANSS评分比较差异无统计学意义(P>0.05);治疗后,实验组PANSS评分低于对照组,差异有统计学意义(P<0.05)。实验组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论对难治性精神分裂症应用利培酮联合奥氮平治疗,可显著提高治疗效果,降低PANSS评分,同时可以减少不良反应,值得推广。

Objective To study the clinical effect of risperidone combined with olanzapine in the treatment of refractory schizophrenia.Methods A total of 80 patients with refractory schizophrenia were divided into experimental group and control group according to the random numerical table,each with 40 cases.The control group was treated with risperidone alone,and the experimental group was treated with risperidone and olanzapine.The therapeutic effects,incidence of adverse reactions,and positive and negative symptoms scale(PANSS)score before and after treatment were compared between the two groups.Results The total effective rate of treatment 95.00%in the experimental group was significantly higher than 72.50%in the control group,and the difference was statistically significant(P<0.05).The experimental group had PANSS scores of(81.24±12.56)points before treatment and(52.45±1.32)points after treatment;the control group had PANSS score of(81.35±12.67)points before treatment and(67.87±1.45)points after treatment.Before treatment,there was no statistically significant difference in PANSS score between the two groups(P>0.05).After treatment,the PANSS score of the experimental group was lower than that of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the experimental group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The use of risperidone and olanzapine in the treatment of refractory schizophrenia can better improve the patient’s therapeutic effect,reduce the PANSS score and adverse reactions,which is worthy of promotion.